Worth reading
62In focus
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
500
¥ million (year-on-year increase in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationFiscal year ending March 2027: Second Quarter (Six-Month)7 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥1,499 million+50.0%
Operating profit¥0 million
Ordinary income¥7 million
Net income¥4 million
Selling, general and administrative expenses¥967 million
Results for the three months of the current quarter
Net Sales
¥732 million
Operating profit (loss)
¥-59 million
Full-year earnings forecast
Regenerative medicine products business revenue
¥2,070 million
Regenerative medicine contract business revenue
¥640 million
Laboratory site business revenue
¥360 million
Total revenue
¥3,070 million
Gross profit
¥2,000 million
Selling, general and administrative expenses
¥1,900 million
Operating profit (loss)
¥100 million
Ordinary profit or loss
¥110 million
Net income (loss)
¥100 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Maintaining demand¥126 million
- Provision of know-how for Teijin's commissioned business ran its course¥-98 million
- JACC revenue¥319 million
- JASMINE revenue¥56 million
- Nepic and Ocural revenue¥7 million
- General customer contract revenue¥87 million
- Labsite Business revenue¥1 million
- Other factors¥-122 million
New initiatives
- Domestic sales partnership for ジャスミン (Jasmine) with Maruho
- Collaboration with OSB on knee joint preservation treatment
- Establishment of the German subsidiary Japan Tissue Engineering Europe GmbH
- Product development to commercialize a research-use intestinal epithelial model
- Establishment of foundational technology for hair follicle organoids
Key KPIsA metric the company considers important as a management benchmark.
- Number of ジャック (Jack) orders (first half)210 Example
- Cumulative ジャック (Jack) orders for the current fiscal year (including orders scheduled for the second half)326 Example
- Number of facilities contracted for OA (osteoarthritis)158 Facility
- Cumulative number of facilities ordering for OA (osteoarthritis) in the current fiscal year103 Facility
- Annual target for ジャック (Jack)350 Example
Segment results
Regenerative medicine products business
Net Sales
¥1,144 million
Year-on-year (%)80
Operating profit (loss)
¥405 million
Regenerative medicine contract services business
Net Sales
¥215 million
Year-on-year (%)-5
Operating profit (loss)
¥117 million
Labsite business
Net Sales
¥139 million
Year-on-year (%)1
Operating profit (loss)
¥23 million
Market Size / Share
- 150,000 peopleDetailsPotential patients with vitiligo
- 13,500 cases/yearDetailsNumber of osteotomy procedures
- 60 %DetailsPercentage of osteotomy procedures performed in combination with JACC
- 10,000,000 peopleDetailsMarket size for knee osteoarthritis
Number of employees
Number of Employees200 people
Reference dateEnd of March 2026
Capital expenditures
¥75 million acquisitions of tangible and intangible fixed assets, first-half actual
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | Fiscal year ending March 2027: Second Quarter (Six-Month) |
| Net Sales | ¥1,499 million (YoY +50.0%) |
| Operating profit | ¥0 million |
| Ordinary income | ¥7 million |
| Net income | ¥4 million |
| Selling, general and administrative expenses | ¥967 million |
| Results for the three months of the current quarter | Net Sales ¥732 million / Operating profit (loss) ¥-59 million |
| Full-year earnings forecast | Regenerative medicine products business revenue ¥2,070 million / Regenerative medicine contract business revenue ¥640 million / Laboratory site business revenue ¥360 million / Total revenue ¥3,070 million / Gross profit ¥2,000 million / Selling, general and administrative expenses ¥1,900 million / Operating profit (loss) ¥100 million / Ordinary profit or loss ¥110 million / Net income (loss) ¥100 million |
| Segment results | Regenerative medicine products business Net Sales ¥1,144 million / Year-on-year (%) 80 / Operating profit (loss) ¥405 million / Regenerative medicine contract services business Net Sales ¥215 million / Year-on-year (%) -5 / Operating profit (loss) ¥117 million / Labsite business Net Sales ¥139 million / Year-on-year (%) 1 / Operating profit (loss) ¥23 million |
| Breakdown of Factors Affecting the Change | Factors Maintaining demand / Amount ¥126 million, Factors Provision of know-how for Teijin's commissioned business ran its course / Amount ¥-98 million, Factors JACC revenue / Amount ¥319 million, Factors JASMINE revenue / Amount ¥56 million, Factors Nepic and Ocural revenue / Amount ¥7 million, Factors General customer contract revenue / Amount ¥87 million, Factors Labsite Business revenue / Amount ¥1 million, Factors Other factors / Amount ¥-122 million |
| Key KPIs | Indicator name Number of ジャック (Jack) orders (first half) / Value 210 Example / Year on year against the same period last year Not disclosed, Indicator name Cumulative ジャック (Jack) orders for the current fiscal year (including orders scheduled for the second half) / Value 326 Example / Year on year against the same period last year Not disclosed, Indicator name Number of facilities contracted for OA (osteoarthritis) / Value 158 Facility / Year on year against the same period last year Not disclosed, Indicator name Cumulative number of facilities ordering for OA (osteoarthritis) in the current fiscal year / Value 103 Facility / Year on year against the same period last year Not disclosed, Indicator name Annual target for ジャック (Jack) / Value 350 Example / Year on year against the same period last year Not disclosed |
| Number of employees | Number of Employees 200 people / Reference date End of March 2026 |
| Capital expenditures | ¥75 million (acquisitions of tangible and intangible fixed assets, first-half actual) |
| Market Size / Share | Details Potential patients with vitiligo / Value 150,000 people, Details Number of osteotomy procedures / Value 13,500 cases/year, Details Percentage of osteotomy procedures performed in combination with JACC / Value 60 %, Details Market size for knee osteoarthritis / Value 10,000,000 people |
| New initiatives | Domestic sales partnership for ジャスミン (Jasmine) with Maruho, Collaboration with OSB on knee joint preservation treatment, Establishment of the German subsidiary Japan Tissue Engineering Europe GmbH, Product development to commercialize a research-use intestinal epithelial model, Establishment of foundational technology for hair follicle organoids |
Items this document does not state (15)
Gross Profit MarginOperating profit marginProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Higher orders for ジャック OA (Jack for osteoarthritis), expansion of ジャスミン (Jasmine) facilities and patient education, and the transition of commissioned projects for general customers to a high-value-added phase contributed to higher revenue. Meanwhile, Teijin's commissioned business declined as the provision of know-how ran its course. Temporary IT infrastructure costs of approximately ¥60 million were recorded in the second quarter but were absorbed through efficiency initiatives and other measures.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.